Allergic Bronchopulmonary Aspergillosis Overview
Learn About Allergic Bronchopulmonary Aspergillosis
- Allergic bronchopulmonary aspergillosis
- ABPA
- Allergic bronchopulmonary mycosis
- Aspergillosis, allergic bronchopulmonary
- Hinson-Pepys disease
University Of Arkansas For Medical Sciences
Emily Kocurek is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Little Rock, Arkansas. Dr. Kocurek and is rated as an Advanced provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. Her top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Pneumonia, Hormone Replacement Therapy (HRT), and Endoscopy. Dr. Kocurek is currently accepting new patients.
David Greenwood is a Pulmonary Medicine provider in Sherwood, Arkansas. Dr. Greenwood has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. His top areas of expertise are Pneumonia, Hospital-Acquired Pneumonia, Atypical Pneumonia, and Lung Metastases. Dr. Greenwood is currently accepting new patients.
Steven Mckee is a Pediatrics specialist and an Internal Medicine provider in Little Rock, Arkansas. Dr. Mckee and is rated as an Experienced provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. His top areas of expertise are Liver Failure, Sickle Cell Disease, Allergic Bronchopulmonary Aspergillosis, Cystic Fibrosis, and Gastrostomy. Dr. Mckee is currently accepting new patients in some locations.
Summary: The investigators hypothesize that a combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year of patients with acute allergic bronchopulmonary aspergillosis (ABPA) compared to itraconazole or prednisolone monotherapy. In this study, 300 subjects aged ≥18 years with acute ABPA will be randomized to treatment with either prednisolone, itraconazole, or...
Summary: While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities. In a previous study, the authors have demonstrated that 22% of subjects with CPA fulfilled the obligatory criteria for ABPA. While the preferable therapy in patients with ABPA is systemic glucocorticoids, th...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center